Cover ImageSALE
Market Research Report

Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 603605
Published Content info 102 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022
Published: February 6, 2018 Content info: 102 Pages
Description

About Hepatic Encephalopathy (HE) Therapeutics

HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.

Technavio's analysts forecast the global hepatic encephalopathy (HE) therapeutics market to grow at a CAGR of 5.35% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global hepatic encephalopathy (HE) therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ASKA Pharmaceutical
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

Market driver

  • Availability of patient-focused programs to assist disease management
  • For a full, detailed list, view our report

Market challenge

  • Late and inaccurate diagnosis
  • For a full, detailed list, view our report

Market trend

  • Technological advances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR20766

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY PRODUCT

  • Overview
  • Comparison by product
  • NADs
  • Antibiotics
  • Others
  • Market opportunity by product

PART 10: MARKET SEGMENTATION BY DISEASE SEVERITY

  • Overview
  • CHE
  • OHE

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas
  • EMEA
  • APAC
  • Key leading countries
  • Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 15: MARKET TRENDS

  • Technological advances
  • Emergence of novel treatment targets

PART 16: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 17: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ASKA Pharmaceutical
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

PART 18: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Interorgan ammonia metabolism in healthy liver
  • Exhibit 02: WHC classification of HE
  • Exhibit 03: Recommended treatment pathway for HE
  • Exhibit 04: Parent market
  • Exhibit 05: Global CNS disorders drugs market: Segments
  • Exhibit 06: Market characteristics
  • Exhibit 07: Global HE therapeutics market: Segments
  • Exhibit 08: Market definition: Inclusions and exclusions checklist
  • Exhibit 09: Market size 2017
  • Exhibit 10: Validation techniques employed for market sizing 2017
  • Exhibit 11: Global HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 12: Global HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 13: Five forces analysis 2017
  • Exhibit 14: Five forces analysis 2022
  • Exhibit 15: Bargaining power of buyers
  • Exhibit 16: Bargaining power of suppliers
  • Exhibit 17: Threat of new entrants
  • Exhibit 18: Threat of substitutes
  • Exhibit 19: Threat of rivalry
  • Exhibit 20: Market condition: Five forces 2017
  • Exhibit 21: Pipeline landscape by development phase
  • Exhibit 22: Key clinical trials
  • Exhibit 23: Global HE therapeutics market: Segmentation by product 2017-2022 (%)
  • Exhibit 24: Comparison by product
  • Exhibit 25: Global NAD HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 26: Global NAD HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Global antibiotic HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 28: Global antibiotic HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Global other HE therapeutics market 2017-2022 ($ millions)
  • Exhibit 30: Global other HE therapeutics market: Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Market opportunity by product
  • Exhibit 32: Customer landscape
  • Exhibit 33: Global HE therapeutics market: Segmentation by geography 2017-2022 (%)
  • Exhibit 34: Regional comparison
  • Exhibit 35: HE therapeutics market in Americas 2017-2022 ($ millions)
  • Exhibit 36: HE therapeutics market in Americas: Year-over-year growth 2018-2022 (%)
  • Exhibit 37: HE therapeutics market in EMEA 2017-2022 ($ millions)
  • Exhibit 38: HE therapeutics market in EMEA: Year-over-year growth 2018-2022 (%)
  • Exhibit 39: HE therapeutics market in APAC 2017-2022 ($ millions)
  • Exhibit 40: HE therapeutics market in APAC: Year-over-year growth 2018-2022 (%)
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: ASKA Pharmaceutical: Overview
  • Exhibit 49: ASKA Pharmaceutical: Business segments
  • Exhibit 50: ASKA Pharmaceutical: Organizational developments
  • Exhibit 51: ASKA Pharmaceutical: Segment focus
  • Exhibit 52: ASKA Pharmaceutical: Key offerings
  • Exhibit 53: ASKA Pharmaceutical: Key customers
  • Exhibit 54: COSMO PHARMACEUTICALS: Overview
  • Exhibit 55: COSMO PHARMACEUTICALS: Business segments
  • Exhibit 56: COSMO PHARMACEUTICALS: Organizational developments
  • Exhibit 57: COSMO PHARMACEUTICALS: Segment focus
  • Exhibit 58: COSMO PHARMACEUTICALS: Key offerings
  • Exhibit 59: COSMO PHARMACEUTICALS: Key customers
  • Exhibit 60: Mallinckrodt: Overview
  • Exhibit 61: Mallinckrodt: Business segments
  • Exhibit 62: Mallinckrodt: Organizational developments
  • Exhibit 63: Mallinckrodt: Geographic focus
  • Exhibit 64: Mallinckrodt: Segment focus
  • Exhibit 65: Mallinckrodt: Key offerings
  • Exhibit 66: Mallinckrodt: Key customers
  • Exhibit 67: Valeant: Overview
  • Exhibit 68: Valeant: Business segments
  • Exhibit 69: Valeant: Organizational developments
  • Exhibit 70: Valeant: Geographic focus
  • Exhibit 71: Valeant: Segment focus
  • Exhibit 72: Valeant: Key offerings
  • Exhibit 73: Valeant: Key customers
Back to Top